In brief: Select Vaccines, Psiron, Visiomed
Thursday, 21 April, 2005
Select Vaccines' (ASX:SLT) hepatitis E diagnostics kits have gained CE Mark approval for sale in the European Union. The company will sell the kits from June this year through its licencee, Genelabs
Psiron (ASX:PSX) has presented new data at a US medical conference confirming the anti-cancer effect in in vitro trials of its Coxsackievirus A21 virotherapy in cancer cell lines for breast, prostate and colon cancer and multiple myeloma.
Visiomed (ASX:VSG) subsidiary InfaMed has begun to sell its Funhaler children's asthma spacer device in Australian pharmacies.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
